Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for AML

HealthTree Podcast for AML

×  

Follow This Show

Stay in the know about new episodes and updates.
HealthTree Podcast for AML brings you patient-led interviews of the world's top AML researchers. Call in live at showtime to ask questions directly to the experts and to learn about the latest innovation in straightforward terms that are easy to understand.

Upcoming Broadcasts

Allogeneic stem cell transplantation is the only curative option for patients battling acute myeloid leukemia. However, a significant number of patients will relapse after transplant. Innovative research and therapies are needed in order to improve outcomes in AML patients. The drug Jakafi (ruxolitinib), a kinase inhibitor, is being explored in a current clinical trial as it may help reduce the risk of relapse. Other therapies such as pre-emptive donor lymphocyte infusions, hypomethylating agents and FLT3 inhibitors combined with donor lymphocyte infusions, CAR T-cell and CAR-NK cells are some of the options being explored. Join us live on Wednesday, October 5th at 1:30 pm EST to hear from Dr. Gabriela Hobbs with Massachusetts General Hospital who will be discussing her clinical trial using Jakafi (ruxolitinib) after allogeneic stem cell transplant as well as other therapies to reduce relapse risk. There will be time at the end of the show to ask Dr. Hobbs your questions directly! Thank you to our episode sponsor, Bristol Myers Squibb.
  • by HealthTree Podcast for AML
  • in Health
  • 01:30

On-Demand Episodes

The IDH mutation can be found in approximately 20% of adult AML cases. Isocitrate dehydrogenase isoform 1 and 2 or IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with... more

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the... more

The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients. It occurs in up to 37% of adult patients with AML. FLT3 mutations have been harder to treat with poor outcomes, however, with... more

Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets CD123-positive AML cells.... more

Immunotherapy is one of the most promising areas of cancer research. Drugs like checkpoint inhibitors, monoclonal and bispecific anitbodies, antibody drug conjugates and CAR-T cell therapy are all extensively being studied in AML.... more

About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target... more

There is a tremendous amount of progress being made in AML. It was remarkable to see the significant work being done in the field of AML at the recent American Society of Hematology (ASH) conference in Atlanta in December 2021. AML... more

Progress in understanding AML and developing therapies that treat this blood cancer is occurring at an astounding pace. In this radio show, Dr. James Blachly, an AML expert from the James Comprehensive Cancer Center at Ohio State... more

The use of the immune system to treat patients with AML is being heavily pursued as a strategy to more effectively fight AML and give patients with relapsed or refractory disease a better chance at achieving remission or a cure.... more

Dr. Gabriel Mannis of the Stanford Cancer Institute is studying what could become the first all oral therapy for newly diagnosed AML. The combination of venetoclax and decitabine with cedazuridine (ASTX727) would provide older adults... more

Comments

 comments